Eiger BioPharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:EIGR)

Analyst Price Target for EIGR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$25.00

▲ +205.62% Upside Potential

This price target is based on 2 analysts offering 12 month price targets for Eiger BioPharmaceuticals in the last 3 months. The average price target is $25.00, with a high forecast of $28.00 and a low forecast of $22.00. The average price target represents a 205.62% upside from the last price of $8.18.

Buy

The current consensus among 2 investment analysts is to buy stock in Eiger BioPharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/29/2019

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/27/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/26/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/25/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/23/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/21/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/19/2021	Wedbush	Reiterated Rating	Buy	$22.00	Medium	i Rating by Liana Moussatos at Wedbush
9/29/2020	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	Medium	i
9/1/2020	Wedbush	Reiterated Rating	Buy	$32.00	High	i Rating by Liana Moussatos at Wedbush
6/4/2020	Wedbush	Reiterated Rating	Buy	$34.00	High	i Rating by L. Moussatos at Wedbush
4/3/2020	Wedbush	Reiterated Rating	Buy	$35.00 ➝ $33.00	High	i Rating by L. Moussatos at Wedbush
3/24/2020	Wedbush	Reiterated Rating	Outperform		Medium	i Rating by L. Moussatos at Wedbush
1/22/2020	LADENBURG THALM/SH SH	Boost Price Target	Buy	$28.00 ➝ $31.00	Low	i
1/6/2020	Wedbush	Reiterated Rating	Buy	$35.00	Low	i
12/16/2019	Gilford Securities	Initiated Coverage	Average		Medium	i
11/11/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	High	i
8/12/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	High	i
6/26/2019	KeyCorp	Initiated Coverage	Overweight	$22.00 ➝ $10.72	Low	i
6/26/2019	Citigroup	Initiated Coverage	Buy	$22.00 ➝ $22.00	Low	i
6/18/2019	Wedbush	Reiterated Rating	Outperform	$35.00	Low	i Rating by Liana Moussatos at Wedbush
6/18/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	High	i
5/16/2019	Wedbush	Reiterated Rating	Buy	$35.00	Low	i Rating by Liana Moussatos at Wedbush
4/24/2019	Wedbush	Lower Price Target	Outperform	$43.00 ➝ $35.00	Low	i Rating by Liana Moussatos at Wedbush
4/12/2019	Wedbush	Set Price Target	Buy	$43.00	High	i Rating by Liana Moussatos at Wedbush
3/26/2019	Wedbush	Reiterated Rating	Buy	$43.00	Low	i Rating by Liana Moussatos at Wedbush
3/19/2019	Wedbush	Set Price Target	Buy	$43.00	Medium	i Rating by Liana Moussatos at Wedbush
2/19/2019	Wedbush	Reiterated Rating	Buy	$43.00	Low	i Rating by Liana Moussatos at Wedbush
1/28/2019	Robert W. Baird	Initiated Coverage	Outperform	$47.00	Medium	i
12/19/2018	BTIG Research	Boost Price Target	Buy	$44.00 ➝ $47.00	High	i
10/19/2018	Wedbush	Set Price Target	Buy	$55.00	Low	i Rating by Liana Moussatos at Wedbush
10/18/2018	Oppenheimer	Set Price Target	Buy	$26.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$28.00	High	i Rating by Michael Higgins at LADENBURG THALM/SH SH
9/10/2018	Wedbush	Set Price Target	Buy	$53.00	Low	i Rating by Liana Moussatos at Wedbush
8/14/2018	Oppenheimer	Set Price Target	Buy	$26.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/13/2018	Wedbush	Set Price Target	Buy	$53.00	Low	i Rating by Liana Moussatos at Wedbush
5/30/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$24.00	Low	i
5/18/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$28.00	High	i
5/17/2018	Oppenheimer	Set Price Target	Buy	$26.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/17/2018	BTIG Research	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $39.00	High	i
5/17/2018	Wedbush	Reiterated Rating	Outperform	$53.00 ➝ $36.00	High	i
5/11/2018	Oppenheimer	Set Price Target	Buy	$26.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/9/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$24.00	High	i Rating by M. Kumar at B. Riley
4/26/2018	Wedbush	Reiterated Rating	Outperform	$36.00	Medium	i
3/22/2018	Wedbush	Lower Price Target	Outperform	$36.00 ➝ $34.00	High	i
3/21/2018	Oppenheimer	Reiterated Rating	Buy		High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
3/12/2018	Oppenheimer	Set Price Target	Buy	$26.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018	Oppenheimer	Set Price Target	Buy	$26.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$35.00 ➝ $17.00	High	i
1/3/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy ➝ Buy	$32.00	High	i
12/7/2017	Oppenheimer	Set Price Target	Buy	$34.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/25/2017	Wedbush	Reiterated Rating	Buy		N/A	i Rating by L. Moussatos at Wedbush
10/23/2017	Oppenheimer	Set Price Target	Buy	$34.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/19/2017	Roth Capital	Initiated Coverage	Buy ➝ Buy	$35.00	N/A	i Rating by M. Higgins at Roth Capital
9/25/2017	Oppenheimer	Reiterated Rating	Buy	$34.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/15/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$36.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/14/2017	Wedbush	Reiterated Rating	Ourperform	$34.00	Low	i Rating by L. Moussatos at Wedbush
7/14/2017	BTIG Research	Initiated Coverage	Buy	$32.00	High	i
6/21/2017	Wedbush	Reiterated Rating	Outperform	$28.00 ➝ $34.00	High	i Rating by L. Moussatos at Wedbush
6/8/2017	Oppenheimer	Set Price Target	Buy	$34.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/15/2017	Jefferies Financial Group	Reiterated Rating	Buy	$28.00 ➝ $27.00	Medium	i
5/10/2017	Oppenheimer	Set Price Target	Buy	$34.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/22/2017	Oppenheimer	Set Price Target	Buy	$34.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/8/2017	Oppenheimer	Set Price Target	Buy	$34.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/8/2017	Piper Jaffray Companies	Set Price Target	Buy	$36.00	Medium	i Rating by Edward Tenthoff at Piper Jaffray Companies
4/7/2017	Jefferies Financial Group	Reiterated Rating	Buy	$28.00	High	i
3/24/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
1/11/2017	Oppenheimer	Set Price Target	Buy	$34.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/11/2016	Oppenheimer	Set Price Target	Buy	$34.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/1/2016	Oppenheimer	Set Price Target	Buy	$34.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/21/2016	Oppenheimer	Reiterated Rating	Outperform	$34.00	N/A	i
11/8/2016	Wedbush	Reiterated Rating	Outperform	$34.00 ➝ $36.00	N/A	i Rating by Heather Behanna at Wedbush
10/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$33.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/11/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i Rating by Heather Behanna at Wedbush
7/5/2016	Oppenheimer	Initiated Coverage	Outperform	$34.00	N/A	i
6/13/2016	Wedbush	Reiterated Rating	Buy	$36.00	N/A	i Rating by Heather Behanna at Wedbush
6/1/2016	Wedbush	Initiated Coverage	Outperform	$36.00	N/A	i Rating by H. Behanna at Wedbush
5/16/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/21/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$30.00 ➝ $33.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies

(Data available from 4/21/2016 forward)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

Today's Range

Now: $8.18

$7.85

$8.20

50 Day Range

MA: $9.09

$8.03

$10.47

52 Week Range

Now: $8.18

$6.76

$13.99

Volume

163,511 shs

Average Volume

258,468 shs

Market Capitalization

$277.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Eiger BioPharmaceuticals?

The following sell-side analysts have issued research reports on Eiger BioPharmaceuticals in the last twelve months: LADENBURG THALM/SH SH, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for EIGR.

What is the current price target for Eiger BioPharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eiger BioPharmaceuticals in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 205.6%. LADENBURG THALM/SH SH has the highest price target set, predicting EIGR will reach $28.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $22.00 for Eiger BioPharmaceuticals in the next year.
View the latest price targets for EIGR.

What is the current consensus analyst rating for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EIGR will outperform the market and that investors should add to their positions of Eiger BioPharmaceuticals.
View the latest ratings for EIGR.

What other companies compete with Eiger BioPharmaceuticals?

Other companies that are similar to Eiger BioPharmaceuticals include Scholar Rock, Cortexyme, Coherus BioSciences, Ocugen, Curis, Vaxcyte, Passage Bio, Aligos Therapeutics, Black Diamond Therapeutics, Adverum Biotechnologies, TCR2 Therapeutics, Taysha Gene Therapies, Sutro Biopharma, Aerie Pharmaceuticals and Cellectis.

How do I contact Eiger BioPharmaceuticals' investor relations team?

Eiger BioPharmaceuticals' physical mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company's listed phone number is 650-272-6138 and its investor relations email address is [email protected] The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

NASDAQ:EIGR - Eiger BioPharmaceuticals Stock Price Target and Predictions

Analyst Price Target for EIGR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Eiger BioPharmaceuticals?

What is the current price target for Eiger BioPharmaceuticals?

What is the current consensus analyst rating for Eiger BioPharmaceuticals?

What other companies compete with Eiger BioPharmaceuticals?

How do I contact Eiger BioPharmaceuticals' investor relations team?